To summarize current indications, treatment approaches, and reported outcomes of electrochemotherapy (ECT) in pediatric patients, emphasizing the systematic review aspect.
Key Findings:
Bleomycin is the most commonly used chemotherapeutic agent in ECT for pediatric patients.
ECT has shown promise in treating refractory or inoperable pediatric tumors and vascular anomalies.
A total of 127 pediatric patients were studied across the included literature, with a pooled mean age of 8.5 years, indicating a focus on younger demographics.
Interpretation:
ECT may provide a valuable treatment option for pediatric patients with specific tumors and vascular anomalies, despite limited data and concerns regarding long-term effects, highlighting the need for standardized protocols.
Limitations:
Limited number of studies specifically focused on pediatric populations.
Inconsistent reporting of bleomycin dosing and treatment parameters across studies.
Potential bias due to the inclusion of studies with mixed adult and pediatric cohorts.
Conclusion:
This review highlights the potential of ECT in pediatric oncology and vascular treatments, advocating for further research to establish standardized protocols and long-term safety, while addressing the limitations identified.
